Diana Brainard
Chief Executive Officer at Kalaris Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Kalaris Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Nektar Therapeutics May 23, 202587.8%
-
Kalaris Therapeutics Inc. May 11, 202387.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2026 | Nektar Therapeutics | Grant or award | +2,000 | — | — |
| Nov 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −8,706 | $0.55 | $4,788 |
| Nov 5, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −10,609 | $0.86 | $9,124 |
| Oct 21, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −9,752 | $0.78 | $7,607 |
| Oct 3, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −1,493 | $0.81 | $1,209 |
| Aug 20, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −5,390 | $0.74 | $3,989 |
| Aug 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −3,091 | $0.76 | $2,349 |
| Aug 5, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −10,847 | $0.73 | $7,918 |
| Jul 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −9,731 | $0.75 | $7,298 |
| Jul 2, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −1,489 | $0.72 | $1,072 |
| May 21, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −5,149 | $0.79 | $4,068 |
| May 17, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −3,075 | $0.75 | $2,306 |
| May 3, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −10,240 | $0.80 | $8,192 |
| Apr 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −9,601 | $0.75 | $7,201 |
| Apr 2, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −1,533 | $0.77 | $1,180 |
Questions about Diana Brainard
What boards is Diana Brainard on?
Diana Brainard sits on the boards of Kalaris Therapeutics Inc. and Nektar Therapeutics.
What company is Diana Brainard the CEO of?
Diana Brainard is Chief Executive Officer of Kalaris Therapeutics Inc.
How long has Diana Brainard served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.